Form 4: Alumis CSO David Goldstein Reports Significant Equity Grants and Holdings

Alumis Inc.'s Chief Scientific Officer, David M. Goldstein, reported the acquisition of 27,000 restricted stock units and 107,950 stock options as part of compensation, alongside existing beneficial ownership.

Summary

• David M. Goldstein, Chief Scientific Officer of Alumis Inc. (ALMS), acquired 27,000 shares of common stock through a Restricted Stock Unit (RSU) grant on July 29, 2025.
• The RSU grant vests 25% on August 1, 2026, with the remaining shares vesting in equal quarterly installments over the subsequent 12 quarters, contingent on continuous service.
• Mr. Goldstein also acquired 107,950 stock options on July 29, 2025, with an exercise price of $3.95 per share and an expiration date of July 28, 2035.
• These stock options vest 25% on July 29, 2026, and the remainder vests in equal monthly installments over the following 36 months, subject to continuous service.
• Direct beneficial ownership of common stock following these transactions is 29,115 shares, which includes 2,115 shares acquired on May 20, 2025, under the Issuer's 2024 Employee Stock Purchase Plan.
• Indirect beneficial ownership includes 207,903 shares held by the Baily Goldstein Living Trust, 8,994 shares by family members, and 1,000 shares by the Jacqueline Goldstein Trust.
• Mr. Goldstein serves as a trustee for both the Baily Goldstein Living Trust and the Jacqueline Goldstein Trust, having become trustee for the latter on March 26, 2025.
• A Power of Attorney was granted on June 24, 2025, to Roy Hardiman, John Schroer, and Sanam Pangali of Alumis Inc. to prepare and file SEC reports on behalf of Mr. Goldstein.

Sentiment

Score: 7

Explanation: The sentiment is positive for the reporting person due to significant equity grants, which align their interests with the company's long-term performance. For the company, it reflects standard executive compensation and retention practices, generally viewed as neutral to slightly positive.

Positives

• The grants of 27,000 Restricted Stock Units and 107,950 stock options represent significant equity compensation for the Chief Scientific Officer, aligning his interests with long-term shareholder value.
• The vesting schedules for both RSUs and stock options are designed to incentivize long-term retention and continuous service of a key executive.

Future Outlook

The filing does not provide forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an insider's equity transactions.

Industry Context

This filing is a standard disclosure of an executive's equity compensation and holdings, which is common practice across publicly traded companies. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Related Party Transactions

• The acquisition of 27,000 Restricted Stock Units and 107,950 stock options are transactions between the company and a key executive (Chief Scientific Officer), which are considered related party transactions.
• Indirect beneficial ownership includes shares held by the Baily Goldstein Living Trust and the Jacqueline Goldstein Trust, for which the reporting person serves as trustee, and shares held by family members residing in his primary residence.

Stakeholder Impact

• Shareholders: The grants represent potential future dilution from the issuance of new shares upon vesting and exercise, but also serve to retain a key executive.
• Reporting Person (David M. Goldstein): Significantly increases his equity stake and long-term incentive compensation in Alumis Inc.

Next Steps

• Vesting of 25% of Restricted Stock Units on August 1, 2026, with subsequent quarterly vesting over 12 quarters.
• Vesting of 25% of stock options on July 29, 2026, with subsequent monthly vesting over 36 months.
• Continued compliance with SEC filing requirements for future changes in beneficial ownership.

Key Dates

Keywords

ALMS, Alumis Inc., David Goldstein, Chief Scientific Officer, Form 4, SEC filing, insider transaction, restricted stock units, RSU, stock options, equity grant, employee stock purchase plan, ESPP